Jupiter Topco LLC Takes Position in Collegium Pharmaceutical, Inc. $COLL

Key Points

• Jupiter Topco LLC acquired 2.15 million Collegium Pharmaceutical shares worth approximately $77.7 million, giving it a 6.6% stake in the company.
• Collegium exceeded quarterly expectations, reporting $1.92 EPS versus the $1.72 consensus and $199.9 million in revenue, up 6.3% year over year.
• The stock opened at $26.44, well below its 52-week high of $50.79, while analysts maintained a “Moderate Buy” consensus and an average price target of $51, despite several recent target cuts.

Jupiter Topco LLC bought a new position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 2,147,072 shares of the specialty pharmaceutical company's stock, valued at approximately $77,743,000. Jupiter Topco LLC owned 6.60% of Collegium Pharmaceutical at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Vident Advisory LLC boosted its stake in Collegium Pharmaceutical by 1.9% in the 3rd quarter. Vident Advisory LLC now owns 15,466 shares of the specialty pharmaceutical company's stock valued at $541,000 after purchasing an additional 281 shares during the period. Quadrant Capital Group LLC increased its position in Collegium Pharmaceutical by 4.2% during the 4th quarter. Quadrant Capital Group LLC now owns 6,996 shares of the specialty pharmaceutical company's stock worth $324,000 after buying an additional 282 shares during the period. Atom Investors LP increased its position in Collegium Pharmaceutical by 5.0% during the 4th quarter. Atom Investors LP now owns 6,124 shares of the specialty pharmaceutical company's stock worth $284,000 after buying an additional 294 shares during the period. Assetmark Inc. lifted its holdings in shares of Collegium Pharmaceutical by 9.3% during the first quarter. Assetmark Inc. now owns 3,923 shares of the specialty pharmaceutical company's stock worth $130,000 after buying an additional 335 shares in the last quarter. Finally, ProShare Advisors LLC lifted its holdings in shares of Collegium Pharmaceutical by 5.0% during the fourth quarter. ProShare Advisors LLC now owns 7,507 shares of the specialty pharmaceutical company's stock worth $348,000 after buying an additional 356 shares in the last quarter.

Collegium Pharmaceutical Price Performance

Shares of NASDAQ COLL opened at $26.44 on Friday. The business has a fifty day moving average price of $33.12 and a two-hundred day moving average price of $35.13. The stock has a market capitalization of $860.89 million, a PE ratio of 21.32 and a beta of 0.73. The company has a debt-to-equity ratio of 3.32, a current ratio of 1.03 and a quick ratio of 0.84. Collegium Pharmaceutical, Inc. has a fifty-two week low of $25.47 and a fifty-two week high of $50.79.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last released its earnings results on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.72 by $0.20. The company had revenue of $199.88 million for the quarter, compared to analyst estimates of $199.62 million. Collegium Pharmaceutical had a return on equity of 91.43% and a net margin of 5.93%.Collegium Pharmaceutical's quarterly revenue was up 6.3% on a year-over-year basis. During the same period in the prior year, the firm posted $1.68 EPS. As a group, equities analysts predict that Collegium Pharmaceutical, Inc. will post 6.51 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently commented on COLL shares. Piper Sandler restated a "neutral" rating and issued a $43.00 price target (down from $45.00) on shares of Collegium Pharmaceutical in a research note on Friday, August 7th. Needham & Company LLC dropped their price objective on shares of Collegium Pharmaceutical from $56.00 to $46.00 and set a "buy" rating for the company in a research note on Thursday, August 6th. Zacks Research cut shares of Collegium Pharmaceutical from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, July 28th. Barclays cut their price objective on shares of Collegium Pharmaceutical from $56.00 to $48.00 and set an "overweight" rating for the company in a report on Wednesday, August 19th. Finally, Wall Street Zen lowered shares of Collegium Pharmaceutical from a "buy" rating to a "hold" rating in a research report on Saturday, August 8th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $51.00.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company's core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company's principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.

Want to see what other hedge funds are holding COLL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source